demonstrated a duration of response of over 3 years for 50% of CLL patients treated with anti-CD19 CAR-T-cell therapy with a limited prevalence of serious adverse events and a median event free survival of 40.5 months (258). This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.